Literature DB >> 21632838

The rationale for using hydroxycarbamide in the treatment of sickle cell disease" (Haematologica 2011;96:488-491). Reply.

Simeon Pollack.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21632838      PMCID： PMC3105659          DOI： 10.3324/haematol.2011.046409

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  6 in total

1.  Reduction of pain episodes and prothrombotic activity in sickle cell disease by dietary n-3 fatty acids.

Authors:  A Tomer; S Kasey; W E Connor; S Clark; L A Harker; J R Eckman
Journal:  Thromb Haemost       Date:  2001-06       Impact factor: 5.249

2.  The rationale for using hydroxycarbamide in the treatment of sickle cell disease.

Authors:  David C Rees
Journal:  Haematologica       Date:  2011-04       Impact factor: 9.941

3.  Flip-flop rates of individual molecular species of phosphatidylcholine in the human red cell membrane.

Authors:  E Middelkoop; B H Lubin; J A Op den Kamp; B Roelofsen
Journal:  Biochim Biophys Acta       Date:  1986-03-13

Review 4.  Hypercoagulability in sickle cell disease: new approaches to an old problem.

Authors:  Kenneth I Ataga; Nigel S Key
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2007

5.  Microvascular endothelial cells express a phosphatidylserine receptor: a functionally active receptor for phosphatidylserine-positive erythrocytes.

Authors:  B N Yamaja Setty; Suhita Gayen Betal
Journal:  Blood       Date:  2007-10-02       Impact factor: 22.113

6.  Transmembrane mobility of phospholipids in sickle erythrocytes: effect of deoxygenation on diffusion and asymmetry.

Authors:  N Blumenfeld; A Zachowski; F Galacteros; Y Beuzard; P F Devaux
Journal:  Blood       Date:  1991-02-15       Impact factor: 22.113
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.